


**Product Name** : KTC1101  
**Cat. No.** : PC-22175  
**CAS No.** : 2764833-47-6  
**Molecular Formula** : C<sub>21</sub>H<sub>26</sub>F<sub>2</sub>N<sub>8</sub>O<sub>3</sub>  
**Molecular Weight** : 476.49  
**Target** : PI3K  
**Solubility** : 10 mM in DMSO



CAS: 2764833-47-6

## Biological Activity

KTC1101 is a potent, selective **pan-PI3K** inhibitor with IC<sub>50</sub> of 3.72 nM for PI3K $\alpha$ , 36.29 nM for PI3K $\beta$ , 1.22 nM for PI3K $\delta$ , and 17.09 nM for PI3K $\gamma$ .

KTC1101 (1  $\mu$ M) robustly inhibits all four PI3K targets with an inhibition rate greater than 90%, while maintaining an inhibition rate of less than 50% for a comprehensive panel of 50 kinases.

KTC1101 demonstrates broad-spectrum anti-proliferative activity across diverse tumor cell lines in vitro, displays superior inhibitory performance in TMD8 cells, when compared to both Copanlisib and ZSTK474.

KTC1101 exhibits a mean GI<sub>50</sub> value of 23.4 nM across a panel of 39 human tumor cell lines, significantly lower than that of ZSTK474 (320 nM) and Copanlisib (134 nM).

KTC1101 demonstrates favorable pharmacological properties and pronounced anti-tumor activity in mice.

KTC1101 has potential to activate tumor immunity through tumor-cell-intrinsic effects and direct T-cell modulation, synergizes with anti-PD-1 therapy.

## References

Peng X, et al. *Mol Cancer*. 2024 Mar 14;23(1):54.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com